Material Event (Form 8-K)

As previously disclosed, on March 17, 2026, Quince Therapeutics, Inc. (the "Company") received a notice from the Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Company had failed to maintain a minimum market value of listed securities ("MVLS") of $50,000,000 over the previous 30 consecutive business days, as required for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A).

On May 20, 2026, the Company received a letter from the Staff stating that, based on the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which reported stockholders' equity of $15,672,000, the Company complies with Nasdaq Listing Rule 5450(b)(1)(A). Accordingly, the Company has regained compliance with Nasdaq's continued listing requirements and this matter is now closed.